Dr Reddy's Labs launches Fesoterodine Fumarate Extended-Release Tablets in US
Hyderabad: Drugmaker, Dr. Reddy's Laboratories Ltd., has announced the launch of the company's Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz (fesoterodine fumarate) Extended-Release Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration (USFDA).
Toviaz is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Fesoterodine fumarate extended-release tablets are indicated for the treatment of Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.
The Toviaz brand had U.S. sales of approximately $211 million MAT for the most recent twelve months ending in May 2022 according to IQVIA.
Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30. Toviaz is a trademark of Pfizer Inc.
Read also: Dr Reddys aims to triple reach to 1.5 billion patients by 2030
